AMERISAFE, Inc. (AMSF) Q3 2024 Earnings Call Transcript Summary
AMERISAFE, Inc. (AMSF) Q3 2024 Earnings Call Transcript Summary
Special dividend declared at $3 per share, in addition to regular quarterly dividends of $0.37.The following is a summary of the AMERISAFE, Inc. (AMSF) Q3 2024 Earnings Call Transcript:
以下是amerisafe公司（AMSF）2024年第三季度業績會議電話記錄摘要：
Financial Performance:
金融業績：
AMERISAFE reported Q3 net income of $14.3 million, or $0.75 per diluted share, and operating net income of $11.1 million, or $0.58 per diluted share.
Gross written premiums for the quarter were $74.9 million, a growth of 5.8% from Q3 of the previous year.
Special dividend declared at $3 per share, in addition to regular quarterly dividends of $0.37.
Book value per share at $16.50 with an operating return on average equity of 14.2%.
Favorable prior year development of $80.5 million from accident years 2017 through 2022.
amerisafe報告第三季度淨利潤爲1430萬美元，每股攤薄股利爲0.75美元，營運淨利潤爲1110萬美元，每股攤薄股利爲0.58美元。
本季度的總保費爲7490萬美元，比上一年第三季度增長了5.8%。
每股特別股息爲3美元，另外還有每股0.37美元的定期季度股息。
每股賬面價值爲16.50美元，平均股本收益率爲14.2%。
來自2017年至2022年事故年度的有利上年發展爲8050萬美元。
Business Progress:
業務進展：
Continued focus on agent engagement and internal efficiencies has led to better top line performance and stronger renewal retention rates of 93.6%.
Significant auditing premium contributions, though moderating, helped boost premium earnings.
Enhanced claims handling processes contributing to favorable loss experiences.
持續關注代理商參與度和內部效率的提升，導致更好的營收表現和更高的續保率達到93.6%。
重要的審計保費貢獻，雖有所減緩，但有助於提升保費收入。
增強理賠處理流程有助於有利的損失經驗。
Opportunities:
機會：
The company is benefiting from stable medical inflation and favorable regulatory fee schedules, ensuring continued profitability in the workers' compensation space.
公司受益於穩定的醫療通脹和有利的監管費用安排，確保在工傷賠償領域持續盈利。
Risks:
風險：
AMERISAFE faces a highly competitive market, although maintaining a strong focus on underwriting discipline and agent engagement to mitigate impacts.
amerisafe面臨激烈競爭的市場，儘管保持高度關注覈保紀律和代理商參與度以減輕影響。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
